Global Radiopharmaceuticals Market Size is valued at USD 6.2 Bn in 2024 and is predicted to reach USD 19.6 Bn by the year 2034 at a 12.7% CAGR during the forecast period for 2025-2034.
Radiopharmaceuticals are medications that incorporate radioactive isotopes. These chemicals are utilized in the field of nuclear medicine for diagnostic and therapeutic applications. They produce detectable radiation that may be captured in images, enabling healthcare workers to visually examine and evaluate the performance of organs, tissues, and physiological processes in the body.
In addition to traditional cancer therapies, the oncologist may consider utilizing radiopharmaceuticals, which employ a blend of radioactive particles and drugs to selectively target and eradicate cancer cells. Radiopharmaceuticals are a specific category of radioactive compounds used in modern medicine. The drugs that contain radionuclides are as follows. Most radiopharmaceuticals employ a radioactive nuclide or radionuclide in combination with a drug or biologically active substance to assess the distribution and localization within the body.
Furthermore, the rising range of radiopharmaceuticals is finding its way into clinical practice, providing doctors with more specific data about the features of various tumour forms. Many cancers are responding to radionuclides as a soothing and curative therapeutic option.
However, the market growth is hampered by the strict regulatory criteria for the safety and health of the radiopharmaceuticals market and the product's inability to prevent fog in environments with dramatic temperature fluctuations or high radiopharmaceuticals because radiopharmaceuticals are costly to create and execute because the market might not be growing quickly, several possible roadblocks could stop the sector from reaching its maximum potential. In all their manifestations, government regulations are thus deemed a barrier to product introduction. Every nation has several regulatory bodies, and every country has its own distinct set of rules. Strict regulatory and product approval processes are expected to slow the growth of the global radiopharmaceutical market.
The catastrophic COVID-19 pandemic impacts have shocked the world's healthcare institutions and crippled their operations. Consequently, hospitals have ramped up testing to save lives and contain the infection. The COVID-19 pandemic has created significant financial difficulties, and governments worldwide have been forced to reduce spending.
The Radiopharmaceuticals Market is segmented based on radioisotope, technology type, indication, source, type, and end user. Based on Radioisotope, the market is segmented into technetium 99, fluorine 18, iodine 131, leutetium 177, yttrium 90, gallium 67, gallium 68, rubidium 82, iodine 123, iodine 125, indium 111, other isotopes. Based on the Indication, the market is divided into oncology, cardiology, gastroenterology, neuroendocrinology, neurology, nephrology, and other indications. Based on the Source, the market is divided into cyclotrons, nuclear reactors, and other sources. Based on the type, the segment is divided into diagnostic and therapeutic. Based on the end Use, the market is divided into hospitals, medical imaging centres, and cancer research institutes.
Based on radioisotope, the market is segmented into technetium 99, fluorine 18, iodine 131, leutetium 177, yttrium 90, gallium 67, gallium 68, rubidium 82, iodine 123, iodine 125, indium 111, other isotopes. Among these, the technetium-99m segment is expected to have the highest growth rate during the forecast period. Technetium-99m (Tc-99m) dominates the radiopharmaceuticals market primarily because of its ideal characteristics for diagnostic imaging and the well-established global infrastructure for its production and distribution. Tc-99m has been used since the 1960s, and infrastructure for its production, transport, and usage is highly developed and regulated.
Based on the Indication, the market is divided into oncology, cardiology, gastroenterology, neuroendocrinology, neurology, nephrology, and other indications. Among these segments, the oncology segment dominates the market. Rising incidence of cancers such as prostate, breast, lung, and neuroendocrine tumours. Cancer is one of the prominent causes of death worldwide, driving high demand for advanced diagnostic and therapeutic solutions. Oncology dominates the radiopharmaceuticals market due to its high disease burden, use of both diagnostic and therapeutic agents, and the rise of personalized medicine through theranostic approaches.
North America leads the radiopharmaceuticals market due to the widespread availability of PET/SPECT scanners and nuclear medicine facilities, along with the high adoption of advanced diagnostics and targeted therapies in hospitals and imaging centres. The region has a large patient pool requiring radiopharmaceutical-based diagnostics and therapies, driven by a significant burden of cancer and other chronic diseases. Additionally, there is a strong demand for personalized medicine and early cancer detection, supported by a robust healthcare system and technological advancements.
| Report Attribute | Specifications |
| Market Size Value In 2024 | USD 6.2 Billion |
| Revenue Forecast In 2034 | USD 19.6 Billion |
| Growth Rate CAGR | CAGR of 12.7 % from 2025 to 2034 |
| Quantitative Units | Representation of revenue in US$ Bn and CAGR from 2025 to 2034 |
| Historic Year | 2021 to 2024 |
| Forecast Year | 2025-2034 |
| Report Coverage | The forecast of revenue, the position of the company, the competitive market structure, growth prospects, and trends |
| Segments Covered | Type, Radioisotope, Indication, Technology / Modality,Indication, Source and End User |
| Regional Scope | North America; Europe; Asia Pacific; Latin America; Middle East & Africa |
| Country Scope | U.S.; Canada; U.K.; Germany; China; India; Japan; Brazil; Mexico; France; Italy; Spain; South East Asia; South Korea |
| Competitive Landscape | Novartis AG, Curium SAS, Bayer AG, Telix Pharmaceuticals Limited, Lantheus Holdings, Inc., GE HealthCare Technologies Inc., Cardinal Health, Inc., Jubilant Pharmova Limited, ITM Isotope Technologies Munich SE, Eli Lilly and Company, AstraZeneca PLC, PharmaLogic Holdings Corp., Life Molecular Imaging GmbH, Bracco Imaging S.p.A., Siemens Healthineers AG, Eckert & Ziegler Strahlen- und Medizintechnik AG, NorthStar Medical Radioisotopes, LLC, Nusano, Inc., Nordion (Canada) Inc., IBA RadioPharma Solutions (Ion Beam Applications S.A.), ANSTO, Yantai Dongcheng Pharmaceutical Group Co., Ltd. and others |
| Customization Scope | Free customization report with the procurement of the report and modifications to the regional and segment scope. Particular Geographic competitive landscape. |
| Pricing And Available Payment Methods | Explore pricing alternatives that are customized to your particular study requirements. |
Chapter 1. Methodology and Scope
1.1. Research Methodology
1.2. Research Scope & Assumptions
Chapter 2. Executive Summary
Chapter 3. Global Radiopharmaceuticals Market Snapshot
Chapter 4. Global Radiopharmaceuticals Market Variables, Trends & Scope
4.1. Market Segmentation & Scope
4.2. Drivers
4.3. Challenges
4.4. Trends
4.5. Investment and Funding Analysis
4.6. Industry Analysis – Porter’s Five Forces Analysis
4.7. Competitive Landscape & Market Share Analysis
4.8. Impact of Covid-19 Analysis
Chapter 5. Market Segmentation 1: By Radioisotope Estimates & Trend Analysis
5.1. By Radioisotope, & Market Share, 2024 & 2034
5.2. Market Size (Value US$ Mn) & Forecasts and Trend Analyses, 2021 to 2034 for the following By Radioisotope:
5.2.1. Technetium 99
5.2.2. Fluorine 18
5.2.3. Iodine 131
5.2.4. Leutetium 177
5.2.5. Yttrium 90
5.2.6. Gallium 67
5.2.7. Gallium 68
5.2.8. Rubidium 82
5.2.9. Iodine 123
5.2.10. Iodine 125
5.2.11. Indium 111
5.2.12. Other Isotopes
Chapter 6. Market Segmentation 2: By Indication Estimates & Trend Analysis
6.1. By Indication & Market Share, 2024 & 2034
6.2. Market Size (Value US$ Mn) & Forecasts and Trend Analyses, 2021 to 2034 for the following By Indication:
6.2.1. Oncology
6.2.2. Cardiology
6.2.3. Gastoenterology
6.2.4. Neuroendocrinology
6.2.5. Neurology
6.2.6. Nephrology
6.2.7. Other Indications
Chapter 7. Market Segmentation 3: By Source Estimates & Trend Analysis
7.1. By Source & Market Share, 2024 & 2034
7.2. Market Size (Value US$ Mn) & Forecasts and Trend Analyses, 2021 to 2034 for the following By Source:
7.2.1. Cyclotrons
7.2.2. Nuclear Reactors
7.2.3. Other Sources
Chapter 8. Market Segmentation 4: By Type Estimates & Trend Analysis
8.1. By Type & Market Share, 2024 & 2034
8.2. Market Size (Value US$ Mn) & Forecasts and Trend Analyses, 2021 to 2034 for the following By Type:
8.2.1. Diagnostic Radiopharmaceuticals
8.2.2. Therapeutic Radiopharmaceuticals
Chapter 9. Market Segmentation 5: By End-Users Estimates & Trend Analysis
9.1. By End-Users & Market Share, 2024 & 2034
9.2. Market Size (Value US$ Mn) & Forecasts and Trend Analyses, 2021 to 2034 for the following By End-Users:
9.2.1. Hospitals
9.2.2. Medical Imaging Centers
9.2.3. Cancer Research Institute
9.2.4. Other End Users
Chapter 10. Market Segmentation 6: By Technology / Modality Estimates & Trend Analysis
10.1. By Technology / Modality & Market Share, 2024 & 2034
10.2. Market Size (Value US$ Mn) & Forecasts and Trend Analyses, 2021 to 2034 for the following Technology / Modality:
10.2.1. SPECT Radiopharmaceuticals
10.2.2. PET Radiopharmaceuticals
10.2.3. Beta-emitting Radiopharmaceuticals
10.2.4. Alpha-emitting Radiopharmaceuticals
Chapter 11. Radiopharmaceuticals Market Segmentation 6: Regional Estimates & Trend Analysis
11.1. North America
11.1.1. North America Radiopharmaceuticals Market revenue (US$ Million) estimates and forecasts By Radioisotope, 2021-2034
11.1.2. North America Radiopharmaceuticals Market revenue (US$ Million) estimates and forecasts By Indication, 2021-2034
11.1.3. North America Radiopharmaceuticals Market revenue (US$ Million) estimates and forecasts By Source, 2021-2034
11.1.4. North America Radiopharmaceuticals Market revenue (US$ Million) estimates and forecasts By Type, 2021-2034
11.1.5. North America Radiopharmaceuticals Market revenue (US$ Million) estimates and forecasts By End-Users, 2021-2034
11.1.6. North America Radiopharmaceuticals Market revenue (US$ Million) estimates and forecasts By Technology / Modality, 2021-2034
11.1.7. North America Radiopharmaceuticals Market revenue (US$ Million) estimates and forecasts By country, 2021-2034
11.2. Europe
11.2.1. Europe Radiopharmaceuticals Market revenue (US$ Million) By Radioisotope, 2021-2034
11.2.2. Europe Radiopharmaceuticals Market revenue (US$ Million) By Indication, 2021-2034
11.2.3. Europe Radiopharmaceuticals Market revenue (US$ Million) By Source, 2021-2034
11.2.4. Europe Radiopharmaceuticals Market revenue (US$ Million) By Type, 2021-2034
11.2.5. Europe Radiopharmaceuticals Market revenue (US$ Million) By End-Users, 2021-2034
11.2.6. Europe Radiopharmaceuticals Market revenue (US$ Million) By Technology / Modality, 2021-2034
11.2.7. Europe Radiopharmaceuticals Market revenue (US$ Million) by country, 2021-2034
11.3. Asia Pacific
11.3.1. Asia Pacific Radiopharmaceuticals Market revenue (US$ Million) By Radioisotope, 2021-2034
11.3.2. Asia Pacific Radiopharmaceuticals Market revenue (US$ Million) By Indication, 2021-2034
11.3.3. Asia Pacific Radiopharmaceuticals Market revenue (US$ Million) By Source, 2021-2034
11.3.4. Asia Pacific Radiopharmaceuticals Market revenue (US$ Million) By Type, 2021-2034
11.3.5. Asia Pacific Radiopharmaceuticals Market revenue (US$ Million) By End-Users, 2021-2034
11.3.6. Asia Pacific Radiopharmaceuticals Market revenue (US$ Million) By Technology / Modality, 2021-2034
11.3.7. Asia Pacific Radiopharmaceuticals Market revenue (US$ Million) by country, 2021-2034
11.4. Latin America
11.4.1. Latin America Radiopharmaceuticals Market revenue (US$ Million) By Radioisotope, (US$ Million) 2021-2034
11.4.2. Latin America Radiopharmaceuticals Market revenue (US$ Million) By Indication, (US$ Million) 2021-2034
11.4.3. Latin America Radiopharmaceuticals Market revenue (US$ Million) By Source, (US$ Million) 2021-2034
11.4.4. Latin America Radiopharmaceuticals Market revenue (US$ Million) By Type, (US$ Million) 2021-2034
11.4.5. Latin America Radiopharmaceuticals Market revenue (US$ Million) By End-Users, (US$ Million) 2021-2034
11.4.6. Latin America Radiopharmaceuticals Market revenue (US$ Million) By Technology / Modality, 2021-2034
11.4.7. Latin America Radiopharmaceuticals Market revenue (US$ Million) by country, 2021-2034
11.5. Middle East & Africa
11.5.1. Middle East & Africa Radiopharmaceuticals Market revenue (US$ Million) By Radioisotope, (US$ Million) 2021-2034
11.5.2. Middle East & Africa Radiopharmaceuticals Market revenue (US$ Million) By Indication, (US$ Million) 2021-2034
11.5.3. Middle East & Africa Radiopharmaceuticals Market revenue (US$ Million) By Source, (US$ Million) 2021-2034
11.5.4. Middle East & Africa Radiopharmaceuticals Market revenue (US$ Million) By Type, (US$ Million) 2021-2034
11.5.5. Middle East & Africa Radiopharmaceuticals Market revenue (US$ Million) By End-Users, (US$ Million) 2021-2034
11.5.6. Middle East a& Africa Radiopharmaceuticals Market revenue (US$ Million) By Technology / Modality, 2021-2034
11.5.7. Middle East & Africa Radiopharmaceuticals Market revenue (US$ Million) by country, 2021-2034
Chapter 12. Competitive Landscape
12.1. Major Mergers and Acquisitions/Strategic Alliances
12.2. Company Profiles
12.2.1. Novartis AG
12.2.2. Curium SAS
12.2.3. Bayer AG
12.2.4. Telix Pharmaceuticals Limited
12.2.5. Lantheus Holdings, Inc.
12.2.6. GE HealthCare Technologies Inc.
12.2.7. Cardinal Health, Inc.
12.2.8. Jubilant Pharmova Limited
12.2.9. ITM Isotope Technologies Munich SE
12.2.10. Eli Lilly and Company
12.2.11. AstraZeneca PLC
12.2.12. PharmaLogic Holdings Corp.
12.2.13. Life Molecular Imaging GmbH
12.2.14. Bracco Imaging S.p.A.
12.2.15. Siemens Healthineers AG
12.2.16. Eckert & Ziegler Strahlen- und Medizintechnik AG
12.2.17. NorthStar Medical Radioisotopes, LLC
12.2.18. Nusano, Inc.
12.2.19. Nordion (Canada) Inc.
12.2.20. IBA RadioPharma Solutions (Ion Beam Applications S.A.)
12.2.21. ANSTO
12.2.22. Yantai Dongcheng Pharmaceutical Group Co., Ltd.
12.2.23. Others
Radiopharmaceuticals Market - By Radioisotope
Radiopharmaceuticals Market – By Source
Radiopharmaceuticals Market – By Type
Radiopharmaceuticals -By Technology / Modality
Radiopharmaceuticals -By Indication
Radiopharmaceuticals- By End User
Radiopharmaceuticals Market – By End User
Radiopharmaceuticals Market By Region-
North America-
Europe-
Asia-Pacific-
Latin America-
Middle East & Africa-